Nanostructural materials that increase mineralization in bone cells and affect gene expression through miRNA regulation and applications of same
A method of inducing mineralization in a bone cell is described. The method comprises contacting a bone cell with a composition comprising nanoparticles. The nanoparticles can be single-walled carbon nanotubes, hydroxyapatite nanoparticles, TiO 2 nanoparticles or silver nanoparticles. The bone cell can be an osteoblast cell. A method for increasing bone mass, bone healing or bone formation is also described which comprises administering to a subject in need thereof an effective amount of a composition comprising nanoparticles. The subject can suffer from a bone disease such as osteoporosis. The subject can suffer from a bone fracture and the method can comprise contacting bone cells near the bone fracture site with the composition. The composition can further comprise a pharmaceutically acceptable carrier.
1. A method comprising:
contacting a bone cell with loose nanoparticles;
wherein the loose nanoparticles are internalized into the bone cell and induce mineralization in the bone cell
wherein the loose nanoparticles are selected from the group consisting of silver nanoparticles, TiO 2 nanoparticles, hydroxyapatite nanoparticles, single-walled carbon nanotubes and combinations thereof.
2. The method of claim 1 , wherein the loose nanoparticles comprise TiO 2 nanoparticles.
3. The method of claim 1 , wherein the loose nanoparticles comprise hydroxyapatite nanoparticles.
4. The method of claim 1 , wherein the loose nanoparticles are coated with a layer of polymer.
5. The method of claim 1 , wherein the loose nanoparticles are attached to one or more targeting moieties.
6. The method of claim 5 , wherein the targeting moieties are selected from the group consisting of antibodies, folates, growth factors, and combinations thereof.
7. The method of claim 1 , wherein the loose nanoparticles are spherical nanoparticles, nanorods, nanotubes or flat sheets.
8. The method of claim 1 , wherein the loose nanoparticles are in a composition which further comprises a pharmaceutically acceptable carrier.
9. The method of claim 1 , wherein the loose nanoparticles comprise silver nanoparticles.
10. The method of claim 9 , wherein the silver nanoparticles have an average diameter of 20±4 nm.
11. The method of claim 1 , wherein the loose nanoparticles comprise single-walled carbon nanotubes.
12. The method of claim 11 , wherein the single-walled carbon nanotubes have a diameter of 0.8 to 1.7 nm.
13. The method of claim 1 , wherein the bone cell is an osteoblast cell.
14. A method for increasing bone mass, bone healing or bone formation comprising administering to a subject in need thereof an effective amount of a composition comprising loose nanoparticles;
wherein the loose nanoparticles are internalized into the bone cell and induce mineralization in the bone cell
wherein the loose nanoparticles are selected from the group consisting of silver nanoparticles, TiO 2 nanoparticles, hydroxyapatite nanoparticles, single-walled carbon nanotubes and combinations thereof.
15. The method of claim 14 , wherein the loose nanoparticles comprise TiO 2 nanoparticles.
16. The method of claim 14 , wherein the loose nanoparticles comprise hydroxyapatite nanoparticles.
17. The method of claim 14 , wherein the loose nanoparticles comprise single-walled carbon nanotubes.
18. The method of claim 14 , wherein the loose nanoparticles are coated with a layer of polymer.
19. The method of claim 14 , wherein the loose nanoparticles are attached to one or more targeting moieties.
20. The method of claim 19 , wherein the targeting moieties are selected from the group consisting of antibodies, folates, growth factors, and combinations thereof.
21. The method of claim 14 , wherein the loose nanoparticles are spherical nanoparticles, nanorods, nanotubes or flat sheets.
22. The method of claim 14 , wherein the loose nanoparticles are in a composition which further comprises a pharmaceutically acceptable carrier.
23. The method of claim 14 , wherein the loose nanoparticles comprise silver nanoparticles.
24. The method of claim 23 , wherein the silver nanoparticles have an average diameter of 20±4 nm.
25. The method of claim 14 , wherein the subject suffers from a bone disease.
26. The method of claim 25 , wherein the bone disease is osteoporosis.
27. The method of claim 14 , wherein the subject suffers from a bone fracture.
28. The method of claim 27 , wherein the method comprises contacting bone cells near the bone fracture site with the loose nanoparticles.